Macroaxis Story

Macroaxis News
  
By Achuva Shats

March 15, 2019

This story will analyze 8 Drugs isntruments to have in your portfolio in April 2019. We will break down the following equities: Stryker Corporation, Align Technology, The Cooper Companies, Chugai Pharmaceutical Co Ltd, Abbott Laboratories, Straumann Holding AG, Becton Dickinson and Company, and Edwards Lifesciences Corporation
The Top 8 Drugs stocks to own in April 2019

This list of potential positions covers Drug manufacturing and delivery. Companies involved in medical and pharmaceutical drug research, manufacturing, and delivery in USA. Please note, we provide buy hold or sell recommendation only in the context of selected investment horizon assuming investor has average attitude towards taking risk. Please also consider using Portfolio Positions Ratings and Equity Ratings tools to further calibrate your research.


Stryker Corporation (SYK)

The company has Net Profit Margin of 26.12 % which may imply that it executes well on its competitive polices and has a good control over its expenditures and variable costs. This is very large. In the same way, it shows Net Operating Margin of 28.06 % which entails that for every 100 dollars of revenue it generated 0.28 of operating income. This firm currently falls under 'Large-Cap' category with total capitalization of 72.31B. Stryker has current Real Value of $175.33 per share. The regular price of the company is $194.04. At this time the company appears to be overvalued. Macroaxis measures value of Stryker from inspecting the company fundamentals such as Return On Equity of 32.73%, Operating Margin of 28.06% and Shares Outstanding of 372.66M as well as reviewing its technical indicators and Probability Of Bankruptcy. In general, we recommend to buy undervalued stocks and to dispose of overvalued stocks since at some point securities prices and their ongoing real values will draw towards each other. Stryker competes with DENTSPLY SIRONA, ResMed, Teleflex Incorporated, Varian Medical, Agilent Technologies, Cigna, China Cord, and Equillium. Stryker Corporation operates as a medical technology company. Stryker Corporation was founded in 1941 and is headquartered in Kalamazoo, Michigan. Stryker operates under Medical Devices classification in USA and is traded on New York Stock Exchange. It employs 36000 people.

Align Technology (ALGN)

The company has return on total asset (ROA) of 15.2 % which means that it generated profit of $15.2 on every $100 spent on asset. This is normal as compared to the sector avarege. Similarly, it shows return on stockholders equity (ROE) of 33.25 % meaning that it created $33.25 on every $100 dollars invested by stockholders. The firm currently falls under 'Large-Cap' category with current market capitalization of 20.18B.
Total Debt
Align Technology shows prevailing Real Value of $199.58 per share. The current price of the firm is $252.33. At this time the firm appears to be overvalued. Macroaxis approximates value of Align Technology from analyzing the firm fundamentals such as Current Valuation of 19.43B, Profit Margin of 20.35% and Return On Equity of 33.25% as well as examining its technical indicators and Probability Of Bankruptcy. In general, we favor to go long with undervalued instruments and to trade away overvalued instruments since at some point assets prices and their ongoing real values will blend.

The Cooper Companies (COO)

The company has Net Profit Margin of 14.22 % which may imply that it executes well on its competitive polices and has a good control over its expenditures and variable costs. This is very large. In the same way, it shows Net Operating Margin of 30.4 % which entails that for every 100 dollars of revenue it generated 0.3 of operating income. This firm currently falls under 'Large-Cap' category with total capitalization of 14.58B. Cooper Companies shows prevailing Real Value of $268.81 per share. The current price of the firm is $295.23. At this time the firm appears to be overvalued. Macroaxis approximates value of Cooper Companies from analyzing the firm fundamentals such as Return On Equity of 11.11%, Profit Margin of 14.22% and Operating Margin of 30.40% as well as examining its technical indicators and Probability Of Bankruptcy. In general, we favor to go long with undervalued instruments and to trade away overvalued instruments since at some point assets prices and their ongoing real values will blend. Cooper Companies shows prevailing Real Value of $268.81 per share. The current price of the firm is $295.23. At this time the firm appears to be overvalued. Macroaxis approximates value of Cooper Companies from analyzing the firm fundamentals such as Profit Margin of 14.22%, Operating Margin of 30.40% and Return On Equity of 11.11% as well as examining its technical indicators and Probability Of Bankruptcy. In general, we favor to go long with undervalued instruments and to trade away overvalued instruments since at some point assets prices and their ongoing real values will blend.

Chugai Pharmaceutical Co Ltd (CHGCY)

The company has return on total asset (ROA) of 8.77 % which means that it generated profit of $8.77 on every $100 spent on asset. This is normal as compared to the sector avarege. Similarly, it shows return on equity (ROE) of 12.84 % meaning that it generated $12.84 on every $100 dollars invested by stockholders. The entity currently falls under 'Large-Cap' category with current market capitalization of 37.57B.

Abbott Laboratories (ABT)

The company has Net Profit Margin of 7.74 % which may imply that it executes well on its competitive polices and has a good control over its expenditures and variable costs. This is very large. In the same way, it shows Net Operating Margin of 23.55 % which entails that for every 100 dollars of revenue it generated 0.24 of operating income. The entity currently falls under 'Mega-Cap' category with total capitalization of 140.27B. Abbott Laboratories shows prevailing Real Value of $69.0025 per share. The current price of the firm is $79.86. At this time the firm appears to be overvalued. Macroaxis approximates value of Abbott Laboratories from analyzing the firm fundamentals such as Profit Margin of 7.74% and Return On Equity of 7.55% as well as examining its technical indicators and Probability Of Bankruptcy. In general, we favor to go long with undervalued instruments and to trade away overvalued instruments since at some point assets prices and their ongoing real values will blend. Abbott Laboratories shows prevailing Real Value of $69.0025 per share. The current price of the firm is $79.86. At this time the firm appears to be overvalued. Macroaxis approximates value of Abbott Laboratories from analyzing the firm fundamentals such as Return On Equity of 7.55% and Profit Margin of 7.74% as well as examining its technical indicators and Probability Of Bankruptcy. In general, we favor to go long with undervalued instruments and to trade away overvalued instruments since at some point assets prices and their ongoing real values will blend.

Straumann Holding AG (STMN.SW)

The company has return on total asset (ROA) of 13.98 % which means that it generated profit of $13.98 on every $100 spent on asset. This is normal as compared to the sector avarege. Similarly, it shows return on equity (ROE) of 30.7 % meaning that it generated $30.7 on every $100 dollars invested by stockholders. This firm currently falls under 'Large-Cap' category with current market capitalization of 11.83B.

Becton Dickinson and Company (BDX)

The company has Net Profit Margin of 6.13 % which may imply that it executes well on its competitive polices and has a good control over its expenditures and variable costs. This is very large. In the same way, it shows Net Operating Margin of 29.79 % which entails that for every 100 dollars of revenue it generated 0.3 of operating income. The entity currently falls under 'Large-Cap' category with total capitalization of 68.32B. Becton Dickinson shows prevailing Real Value of $219.94 per share. The current price of the firm is $253.92. At this time the firm appears to be overvalued. Macroaxis approximates value of Becton Dickinson from analyzing the firm fundamentals such as Return On Equity of 4.91% and Profit Margin of 6.13% as well as examining its technical indicators and Probability Of Bankruptcy. In general, we favor to go long with undervalued instruments and to trade away overvalued instruments since at some point assets prices and their ongoing real values will blend.

Edwards Lifesciences Corporation (EW)

The company has Net Profit Margin (PM) of 19.4 % which may suggest that it has a good control over its expenditures, executes well on its competitive polices, or have a solid pricing strategies. This is very large. Likewise, it shows Net Operating Margin (NOM) of 28.81 % which signify that for every $100 of sales it has a net operating income of 0.29. The entity currently falls under 'Large-Cap' category with market capitalization of 37.35B.
Total Debt
Edwards Lifesciences competes with Digirad, Dynatronics, Encision, EDAP TMS, Electromed, Establishment Labs, and Second Sight. Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States and internationally. Edwards Lifesciences Corporation was founded in 1999 and is headquartered in Irvine, California. Edwards Lifesciences operates under Medical Devices classification in USA and is traded on BATS Exchange. It employs 12800 people.

Current 8 Drugs Recommendations

Competition Technical Indicators

Mean
Deviation
Jensen
Alpha
Sortino
Ratio
Treynor
Ratio
Semi
Deviation
Information
Ratio
Expected
Shortfall
Potential
Upside
Value
At Risk
Maximum
Drawdown
 1.34  0.18  0.17  0.30  0.97  0.11 (1.70)  2.61 (1.55)  11.79 
 3.28  0.16  0.07  0.27  2.88  0.0487 (4.41)  6.94 (4.22)  12.29 
 2.06 (0.68)  0.00 (0.34)  0.00 (0.19)  0.00  5.79 (6.09)  16.42 
 3.21 (0.55)  0.00 (0.04)  0.00 (0.05)  0.00  8.57 (13.16)  28.31 
 20.97  6.34  0.13 (0.51)  19.35  0.12 (70.71)  85.38 (46.06)  222.82 
 2.39  0.49  0.12  1.39  2.82  0.12 (2.64)  5.95 (3.55)  15.96 
 2.69  0.12 (0.03) (0.21)  3.10 (0.0277) (3.04)  5.36 (3.64)  15.97 
 4.53 (0.98)  0.00 (0.15)  0.00 (0.08)  0.00  13.33 (11.76)  45.19 
 0.99  0.09  0.00  0.07  0.00 (0.14)  0.00  2.30 (2.34)  6.74 
 3.34 (0.24)  0.00  0.59  0.00 (0.11)  0.00  7.17 (7.63)  20.74 

About Contributor

Achuva Shats
   Achuva Shats is a Member of Macroaxs Editorial Board. Achuva writes about retail product and service companies from the prospective of a regular consumer and sophisticated investor at the same time. She is passionate about corporate ethics and equality in the workforce View Profile
This story should be regarded as informational only and should not be considered as solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Achuva Shats do not own shares of Macroaxis. Please refer to our Terms of Use for any information regarding our disclosure principles.

Did you try this?

Run Analyst Recommendations Now

   

Analyst Recommendations

Analyst recommendations and target price estimates broken down by several categories
All  Next Launch Analyst Recommendations
See also Stocks Correlation. Please also try Portfolio Rebalancing module to analyze risk-adjusted returns against different time horizons to find asset-allocation targets.
Search macroaxis.com